201 related articles for article (PubMed ID: 24573637)
41. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
42. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
[TBL] [Abstract][Full Text] [Related]
43. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
44. Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Zhou RJ; Xu XY; Liu BX; Dai WZ; Cai MQ; Bai CF; Zhang XF; Wang LM; Lin L; Jia SZ; Wang WH
Int J Mol Med; 2015 Oct; 36(4):1159-64. PubMed ID: 26310668
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Yan W; Liu Y; Yang P; Wang Z; You Y; Jiang T
Oncotarget; 2015 May; 6(13):11676-82. PubMed ID: 25869098
[TBL] [Abstract][Full Text] [Related]
46. Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Ananta JS; Paulmurugan R; Massoud TF
Mol Pharm; 2015 Dec; 12(12):4509-17. PubMed ID: 26559642
[TBL] [Abstract][Full Text] [Related]
47. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
48. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
49. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
51. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
[TBL] [Abstract][Full Text] [Related]
52. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
53. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
54. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Cheng ZX; Yin WB; Wang ZY
Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
[TBL] [Abstract][Full Text] [Related]
55. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
57. miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
Shi L; Wan Y; Sun G; Zhang S; Wang Z; Zeng Y
BioDrugs; 2014 Feb; 28(1):41-54. PubMed ID: 23857508
[TBL] [Abstract][Full Text] [Related]
58. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
59. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
60. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
